CALGARY, Oct. 24, 2014 /PRNewswire/ - Oncolytics
Biotech® Inc. ("Oncolytics" or the "Company") (TSX:ONC;
NASDAQ:ONCY) announced today that it has entered into an
"at-the-market" (ATM) equity distribution agreement with Canaccord
Genuity Inc. acting as sole agent. Under the terms of the
distribution agreement, the Company may, from time to time, sell
shares of its common stock having an aggregate offering value of up
to $20 million through Canaccord
Genuity Inc. The Company will determine, at its sole
discretion, the timing and number of shares to be sold under this
ATM facility.
"Entering into this agreement further improves
our financial flexibility by providing us with another option when
accessing capital," said Dr. Brad
Thompson, President and CEO of Oncolytics.
A shelf registration statement (SEC File No.
333-197633) relating to these securities was declared effective by
the Securities and Exchange Commission on August 4, 2014. The securities may be offered
only by means of a prospectus, including a prospectus supplement,
forming a part of the effective registration statement. When
available, copies of the prospectus supplement and accompanying
base prospectus related to the ATM offering may be obtained from
the Securities and Exchange Commission's website at
http://www.sec.gov or by contacting Canaccord Genuity Inc.,
Attention: Syndicate Department, 99 High Street, 12th Floor,
Boston, Massachusetts 02110,
by telephone at 617-371-3900 or by email at
USecm@canaccordgenuity.com.
This press release does not constitute an offer
to sell or the solicitation of offers to buy any securities of the
Company, and shall not constitute an offer, solicitation or sale of
any security in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Oncolytics Biotech®
Inc.
Oncolytics is a Calgary-based
biotechnology company focused on the development of oncolytic
viruses as potential cancer therapeutics. Oncolytics'
clinical program includes a variety of later-stage, randomized
human trials in various indications using REOLYSIN®, its
proprietary formulation of the human reovirus. For further
information about Oncolytics, please visit:
www.oncolyticsbiotech.com.
This press release contains forward-looking
statements within the meaning of the U.S. Securities Act of 1933,
as amended, and U.S. Securities Exchange Act of 1934, as amended,
and forward-looking information within the meaning of Canadian
securities laws. Statements, other than statements of historical
facts, included in this press release that address activities,
events or developments that Oncolytics expects or anticipates will
or may occur in the future, including such things as the proposed
offering of common shares and the intended use of proceeds and
other such matters are forward-looking statements and
forward-looking information and involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward-looking statements and
forward-looking information. Such risks and uncertainties include,
among others, risks related to the market conditions of the
offering and risks related to the Company's business which may
result in the intended use of proceeds changing. Investors should
consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statement and forward-looking information. Investors are cautioned
against placing undue reliance on forward-looking statements and
forward-looking information. The Company does not undertake to
update these forward-looking statements and forward-looking
information, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.